Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro

American Journal of Cardiology

Volumn 83, Issue 5 A, 1999, Pages 3-12

  Wallis, Robert M ^a   Corbin, Jackie D ^b   Francis, Sharron H ^b   Ellis, Peter ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; GLYCERYL TRINITRATE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE; SILDENAFIL;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ASSAY; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; TISSUE DISTRIBUTION; VASCULAR RING;

EID: 0033522211     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00042-9     Document Type: Article

References (14)

1. Ballard S.A., Gingell C.J., Tang K., Turner L.A., Price M.E., Naylor A.M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 159:1998;2164-2171.
2. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell C. Sildenafil an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction . Int J Impot Res. 8:1996;47-52.
3. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338:1998;1397-1404.
4. Jeremy J.Y., Ballard S.A., Naylor A.M., Miller M.A.W., Angelini G.D. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol. 79:1997;958-963.
5. Fischer T.A., Erbel R., Treese N. Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure. Drugs. 44:1992;928-945.
6. Beavo J.A. Cyclic nucleotide phosphodiesterases functional implications of multiple isoforms . Physiol Rev. 75:1995;725-748.
7. Rybalkin S.D., Bornfeldt K.E., Sonnenburg W.K., Rybalkina I.G., Kwak K.S., Hanson K., Krebs E.G., Beavo J.A. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest. 100:1997;2611-2621.
8. Packham M.A., Mustard J.F. Pharmacology of platelet-affecting drugs. Circulation. 62:(suppl V):1980;V26-V41.
9. Moreland R.B., Goldstein I., Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci. 62:1998;309-318.
10. Morales A., Gingell C., Collins M., Wicker P.A., Osterloh I.H. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res. 10:1998;69-74.
11. Vallance P., Collier J., Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 2:1989;997-1000.
12. Umans J.G., Levi R. Nitric oxide in the regulation of blood flow and arterial pressure. Annu Rev Physiol. 57:1995;771-790.
13. Webb D.J., Freestone S., Allen M.J., Muirhead G.J. Sildenafil citrate and blood-pressure-lowering drugs results of drug interaction studies with an organic nitrate and a calcium antagonist . Am J Cardiol. 83:1999;21C-28C.
14. Sly M.K., Eberhart R.C., Prager M.D. Anti-platelet action of nitric oxide and selective phosphodiesterase inhibitors. Shock. 8:1997;115-118.